DSG’s EDC Enables Human Genome to Achieve Benlysta Drug Objectives

After Benlysta achieved the primary endpoint in Bliss – 52, Human Genome Sciences, is pleased report that the first two pivotal Phase 3 trials involving patients with serologically active systematic lupus erythematous has been completed.  The results have began to prove that Benlysta may in fact possess the potential to become the first approved systematic lupus treatment in decades.

Currently, DSG sustains the HGS study trial through data capture and support management as a result of its eCaseLink EDC software.  The trial study involves roughly 400 electronic case report forms per subject, DSG then supplies critical data report tools, originating from study stipulations, thereby permitting HGS data management personnel to effectively observe and assure data quality.

HGS operated DSG’s exclusive Dashboard within eCaseLink, which quickly locates outstanding items that require attention during the global database lockdown.  Furthermore, the software permitted HGS to blend in a licensed Clinical Trial Management System, as well as a third – party Interactive Voice Response System alongside eCaseLink, thereby establishing an expedient swap of analytical information.